Prevention of ventricular arrhythmias in the congenital long QT syndrome

被引：20

作者：

Viskin S. ^{[1
]}

Fish R. ^{[1
]}

机构：

[1] Department of Cardiology, Sourasky-Tel Aviv Medical Center, Tel Aviv University, Tel Aviv 64239

来源：

Current Cardiology Reports | 2000年 / 2卷 / 6期

关键词：

Flecainide; Nicorandil; Tocainide; Blocker Therapy; Cardiac Pace;

D O I：

10.1007/s11886-000-0033-2

中图分类号：

学科分类号：

摘要：

Life-long therapy is necessary for patients with symptomatic long QT syndrome to prevent arrhythmic death. The merits and limitations of the different therapeutic modalities are discussed. b-blockers remain the mainstay of therapy, but this medication may not be sufficient for cardiac arrest survivors and for those with the LQT3 genotype. "Genotype-specific" therapy, like potassium-channel openers for patients with inadequate potassium outflow (LQT1 and LQT2 genotypes) or sodium-channel blockers for patients with excessive sodium inflow (LQT3), significantly shortens the QT interval, but the effects of these drugs on arrhythmia prevention is less well established. Cardiac pacemakers may be especially beneficial for patients with LQT2 or LQT3 and for those with pause-dependent torsade de pointes. More important is to recognize that device programming for preventing tachyarrhythmias in patients with long QT differs from the standard pacemaker programming. Finally, implantable defibrillators with dual-chamber pacing capability are indicated for patients at high risk for arrhythmic death, including all cardiac arrest survivors. Copyright © 2000 by Current Science Inc.

引用

页码：492 / 497

页数：5

共 48 条

[1]

Schwartz P.J., Priori S.G., The long Q-T syndrome, ANE, 3, pp. 63-67, (1998)

[2]

Viskin S., The long QT syndromes and torsade de pointes, Lancet, 354, pp. 1625-1633, (1999)

[3]

Vincent G.M., Timothy K., Zhang L., Congenital long QT syndrome, Cardiac Electrophysiol Rev, 3, pp. 207-209, (1999)

[4]

Roden D.M., Lazzara R., Rosen M., Et al., Multiple mechanisms in the long QT syndrome. Current knowledge, gaps, and future directions, Circulation, 94, pp. 1996-2012, (1996)

[5]

Antzelevitch C., Sicouri S., Clinical relevance of cardiac arrhythmias generated by after depolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes, J Am Coll Cardiol, 23, pp. 259-277, (1994)

[6]

El-Sherif N., Caref E.B., Yin H., The electrophysiological mechanism of ventricular tachyarrhythmias in the long QT syndrome. Tridimentional mapping of activation and r ecovery patterns, Circ Res, 79, pp. 474-492, (1996)

[7]

Jackman W.M., Friday K.J., Anderson J.L., Et al., The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis, Prog Cardiovasc Dis, 31, pp. 115-172, (1988)

[8]

Kay G.N., Plumb V.J., Arciniegas J.G., Et al., Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients, J Am Coll Cardiol, 2, pp. 806-817, (1983)

[9]

Locati E.H., Maison-Blanche P., Dejode P., Et al., Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: Quantitative analysis of Holter recordings, J Am Coll Cardiol, 25, pp. 1564-1575, (1995)

[10]

Sclarovsky S., Strasberg B., Lewin R., Agmon J., Polymorphous ventricular tachycardia: Clinical features and treatment, Am J Cardiol, 44, pp. 339-345, (1979)

← 1 2 3 4 5 →